Skip to main
TMO

TMO Stock Forecast & Price Target

TMO Analyst Ratings

Based on 18 analyst ratings
Buy
Strong Buy 33%
Buy 61%
Hold 6%
Sell 0%
Strong Sell 0%

Bulls say

Thermo Fisher Scientific is projected to experience revenue growth across its segments, with lab products and services anticipated to grow at a 5.4% compound annual rate in the next three years, although this marks a slowdown from the 16.9% growth rate seen from 2019 to 2024. The company is also expected to gain market share in the Contract Research Organization (CRO) sector, buoyed by favorable trends in biopharma clinical trial outsourcing, which indicates a notable increase in demand for outsourced services. Additionally, the forecast for adjusted earnings per share (EPS) suggests a robust increase at an 8.5% compound annual rate over the next four years, reinforcing a positive financial outlook for the company.

Bears say

Thermo Fisher Scientific has experienced a significant decline in its adjusted EBIT margin, dropping approximately 830 basis points to 22.6% from 2021 to 2024, primarily driven by a corresponding 940-basis-point decrease in adjusted gross margin. The company's adjusted gross margin fell to 42.2%, marking a reduction of about 420 basis points compared to the 46.4% gross margin recorded in 2019. Furthermore, despite a noted improvement in biotech customer sentiment, funding levels in 2025 have started sluggishly, with a nearly 45% year-over-year decline in raised capital in the first half of the year.

TMO has been analyzed by 18 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 61% recommend Buy, 6% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Thermo Fisher Scientific and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Thermo Fisher Scientific (TMO) Forecast

Analysts have given TMO a Buy based on their latest research and market trends.

According to 18 analysts, TMO has a Buy consensus rating as of Dec 30, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $631, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $631, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Thermo Fisher Scientific (TMO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.